Virbac: Stifel raises target price

(CercleFinance.com) - Stifel maintains its 'hold' recommendation on Virbac shares, with a target price raised from E369 to E420, after the animal health group's H1 results were judged solid, with the group clearly reassuring regarding the achievement of annual targets.


The broker notes, however, that confirmed targets for 2024 imply weak revenue growth in Q3 and Q4, and that results for H1 2025 will have a difficult comparison basis.

Trading on a forward-looking P/E of 20x, analysts believe that the share price adequately reflects current fundamentals and a fair risk/reward ratio, it adds.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.